...diseases 2012 Improved Pregnancy Outcomes via Early Detection (IMPROvED) consortium accelopment AG; Metabolomic Diagnostics Ltd.; Pronota N.V....

...Biocartis spun out newco MyCartis (Lausanne, Switzerland), a combination of Pronota and Biocartis' Evalution unit, which...
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...
...patients. Idylla (formerly Apollo) is an automated molecular diagnostic system. Biocartis S.A. , Lausanne, Switzerland Pronota N.V....

...investors also participated (see BioCentury, Nov. 18, 2013) . Newco MyCartis is a combination of Pronota N.V....
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...

...Detection (IMPROvED) consortium to develop a predictive preeclampsia diagnostic. The project, which includes Metabolomic and Pronota...
...time. The partners could not be reached for details. Metabolomic Diagnostics Ltd. , Cork, Ireland Pronota N.V....

...A validation study in 300 women showed that Pronota's mid-gestation preeclampsia screening test correctly identified 80%...
...information from 5,600 women in Australia, New Zealand, the U.K. and Ireland over 8 years. Pronota N.V....

...Chemical Holdings' Molecuence Corp. subsidiary partnered to discover and validate protein biomarkers to diagnose stroke. Pronota...
...protein biomarker discovery platform and MASSterclass protein biomarker verification tool. Further terms were not disclosed. Pronota N.V....

...the total raised in the round to €7.9 million. MedSciences Capital participated in the close. Pronota N.V....

...Venture Management participated. The company raised €4.9 million ($6.9 million) in the round in June. Pronota N.V....